Japan is an aging society, and the number of elderly patients with asthma and chronic obstructive pulmonary disease (COPD) is consequently increasing, with an estimated incidence of approximately 5 million. In 2014, asthma-COPD overlap syndrome (ACOS) was defined by a joint project of Global Initiative for Asthma (GINA) committee and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) committee.
| INTRODUCTION
Japan is an aging society, and the number of elderly patients with asthma and chronic obstructive pulmonary disease (COPD) is consequently increasing, with an estimated incidence of approximately five million. Although airway inflammation plays a role in the pathogenesis of both diseases, the inflammatory cells found in both and the efficacies of drugs are different. COPD and asthma are considered different diseases with different treatment guidelines. [1] [2] [3] [4] However, their clinical symptoms are similar, particularly when they coexist in elderly patients. The coexistence of COPD is a contributing factor for refractory asthma, and therapeutic strategies should be accordingly selected.
Items for COPD coexistent with asthma were added to the Japanese COPD Guidelines for Diagnosis and Therapy, third edition, which was released in June 2009. 3 The Japanese Asthma Prevention and Control
Guidelines, 2012, recommended that asthma with COPD in elderly patients requires early intervention because of a poor prognosis and an early decrease in pulmonary function. 1 Asthma in patients with COPD generally shows a late onset and occurs in the presence of a smoking history, while patients with COPD occasionally exhibit risk factors for asthma or asthmatic symptoms. Therefore, it is difficult to distinguish asthma from COPD.
The characteristics of asthma in elderly patients include a decrease in pulmonary function, particularly small airway obstruction, and rapid airway obstruction because of aging, smoking, and airway remodeling. Asthma coexistent with COPD in elderly patients is generally nonatopic and is associated with a high frequency of complications, such as cardiovascular disease, digestive disorders, and metabolic diseases. Other characteristics of asthma in elderly patients include an increased risk of infection because of low immunity or aspiration and a decreased quality of life and adherence to drugs.
Asthma associated with smoking has higher severity, requires more frequent hospital admission, and causes a rapid decrease in the forced expiratory volume in 1 second (FEV1.0) compared with asthma
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not associated with smoking. Furthermore, the efficacy of inhaled or oral corticosteroids is lower for the former than for the latter.
Patients with features of both asthma and COPD have been recognized. They experience frequent exacerbations and have poor quality of life, a more decline in lung function and high mortality than asthma or COPD alone. 5, 6 However, there was no generally agreed term or defining features for this category of chronic airway obstruction. In 2014, asthma-COPD overlap syndrome (ACOS) was defined by a joint project of Global Initiative for Asthma (GINA) committee and the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) committee.
The main aims of this consensus-based document are to assist clinicians, especially those in primary care or nonpulmonary specialties. 2, 4 This document also shows ACOS is not a single disease. It includes patients with different forms of airway disease. Therefore, the other aims of this document to stimulate research into ACOS.
In this article, we discuss parameters to differentiate asthma and COPD in elderly patients and management strategies for asthma, COPD, and ACOS on the basis of the guidelines of GINA and GOLD.
| DIAGNOSIS AND DIFFERENTIATION: ASTHMA AND COPD
The following diagnostic criteria for asthma were proposed by the Japanese Society of Allergology: attacks of dyspnea, wheezing, chest discomfort, and repeated cough (particularly at night and early morning); reversible airway limitation; airway hypersensitivity; history of atopic factor exposure; airway inflammation; and the absence of other diseases. 1 COPD is diagnosed when FEV1.0% is <70% after bronchodilator inhalation. However, the assessment of FEV1.0% alone has two limitations. First, it can lead to overestimation of the diagnosis in elderly patients and underestimation in patients with a low vital capacity. Therefore, it is important to judge the severity using both FEV1.0% and %FEV1.0 (FEV1.0/FEV1.0 pred). 3, 4 When patients with asthma aged >50 years exhibit symptoms of dyspnea on exertion, cough, sputum, and a history of smoking of >10 pack-years, the coexistence of COPD should be considered. On the other hand, when patients with COPD report a history of asthma, atopic factor exposure, and attacks of wheezing, cough, and dyspnea at night and in the early morning, the coexistence of asthma should be considered. We often see such patients in the clinic; therefore, awareness of the characteristics of patients with ACOS is important.
The syndromic diagnosis of asthma, COPD, and ACOS in elderly patients is shown in Table 1 
| PREVALENCE OF ACOS
Gibson et al. 5 showed prevalence of ACOS patients by gender increased depending on aging. Guidelines 2,4 showed the prevalence rates of ACOS have ranged between 15% and 55%, [6] [7] [8] and concurrent doctordiagnosed asthma and COPD have been reported in between 15% and 20% of patients. [9] [10] [11] [12] In Japan, Nagai et al. 13 In summary, the prevalence of ACOS was found to be at least 15%. compared with the patients with asthma. 16 The clinical features of asthma in elderly patients and COPD are shown in Table 2 
| CLINICAL FEATURES OF ACOS

| TREATMENT OF SYNDROMIC DIAGNOSIS OF ACOS
Smoking cessation is the first step of management for smokers. It decreases the symptoms of wheezing, cough, sputum, and dyspnea and disease severity and improves the patient's quality of life. It also improves airway inflammation and airway obstruction, which leads to prevent a rapid decrease in FEV1.0. Smoking cessation improves the efficacy of ICS and theophylline clearance. 17 Active asthma without COPD decreased pulmonary function compared with inactive asthma. To obtain good control of asthma is very important to maintain lung function; therefore, the use of ICS is strongly recommended for patients with asthma to obtain better control ( Figure 2 ). 18 Pulmonary function shows a more rapid decrease in ACOS patients than in patients with COPD. Therefore, ICS are of beta-2 receptors occurs by the administration of LABAs alone, even in elderly patients, while ICS suppress this downregulation. Therefore, administration of both ICS and LABAs may be effective. The combined administration of ICS and LABAs is easier compared with the separate administration of each drug, and it is expected to lead to higher patient compliance. Furthermore, low-dose theophylline (serum level: approximately 5 μg/mL) has shown anti-inflammatory effects when combined with bronchodilators. However, serum theophylline levels should be measured, particularly in patients with several complications, to prevent theophylline intoxication. Smoking increases leukotriene production in patients with asthma; it has been reported that leukotriene receptor antagonists are more effective than ICS for asthma associated with smoking. 24 The daily activities of ACOS patients are decreased because of dyspnea on exertion. This results in deconditioning and decreased cardiac function and skeletal muscle wasting, which, in turn, leads to less exercise and deterioration of dyspnea, thus creating a vicious circle. To resolve this issue, pulmonary rehabilitation and appropriate respiration techniques and drug administration are recommended; short-acting bronchodilators administered before exercise are also effective.
In summary, ACOS patients should receive a combination of ICS and long-acting bronchodilators LABAs and/or LAMAs after considering the risks and benefits. Depending on the symptoms or severity of disease, other medications or early pulmonary rehabilitation should be additionally considered.
| REFERRAL FOR SPECIALIZED INVESTIGATIONS
Referral for expert advice and further diagnostic evaluation is necessary in the following contexts ( Figure 4 ): (i) Patients with persistent symptoms and/or exacerbations despite treatment; (ii) diagnostic uncertainty, especially if an alternative diagnosis including suspected pulmonary hypertension, cardiovascular disease, and other causes of respiratory symptoms, needs to be excluded; (iii) patients with suspected asthma or COPD with atypical or additional symptoms or signs (eg, hemoptysis, weight loss, night sweat, fever, signs of bronchiectasis, or other structural lung disease) suggest an additional pulmonary diagnosis;(iv) when chronic airways disease is suspected but syndromic features of both asthma and COPD are few; (v) comorbidities present; (vi) referral may be appropriate for issues arising during ongoing management of asthma, COPD, or ACOS, as outlined in the GINA and GOLD strategy reports. 2, 4 In summary, when diagnosis is uncertain or symptoms are atypical or continue in spite of appropriate treatment of ACOS by guidelines' recommendations, referral for specialized investigation is needed.
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